DeCode Enters Bankruptcy, Looks To Sell Assets To Its Former VCs
This article was originally published in The Pink Sheet Daily
Executive Summary
Saddled by $314 million in debt, the Icelandic firm files for Chapter 11 protection.
You may also be interested in...
Trouble In Iceland: DeCODE Scrambles To Escape Cash Crisis
Personalized medicine firm digs its way out of suffocating debt, hoping mystery investors will help the company survive 2009.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.